Molecular Markers of Arterial Hypertension in Patients with Normotony, Pre-Hypertension and Hypertension

Шерстнев, В. В.; Gruden, M. A.; Elistratova, E. I.; Karlina, V. P.; Кузнецова, А. В.; Рыжова, Т В; Ryzhov, V. M.; Sen’ko, O. V.

doi:10.1007/s10517-015-2816-x

Cited by 5 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Having considered all the above, and in agreement with recent literature [24,25], it seems that hypertension may be attributed to autoimmunity. It is well known that hypertension is prevalent in autoimmune disease and is an early symptom of the following renal involvement.…”

Section: Discussionsupporting

confidence: 86%

See 1 more Smart Citation

Study of Antiphospholipid Antibodies in Patients with Arterial Hypertension

et al. 2018

View full text Add to dashboard Cite

Antiphospholipid syndrome (APS) is a multifactorial, autoantibody-mediated disease. Antiphospholipid antibodies (aPL) directed against negatively charged phospholipids or various combinations of phospholipid-binding proteins seem to be an independent pathogenic factor that plays a critical role in APS. Unfortunately, their role in hypertension is not fully elucidated. The aim of our study was to determine aPL titers in hypertension patients and investigate the association of aPL with renal impairment parameters. Forty-seven patients with arterial hypertension (22 males, 46.8% and 25 females, 53.2%), aged 41–85 years old (mean 65.9 ± 10.1 years), and 21 age-sex-matched subjects without severe hypertension as control group (8 males, 13 females, 38.1% vs. 61.9%), mean age 61 ± 11.3 years, were enrolled in this study. Patients with other risk factors like Rheumatoid Arthritis and Systematic Lupus Erythematosus (SLE), both viral and bacterial acute infections, and cancer were excluded from the study. The aPL (anticardiolipin (ACA) and anti-b2GPI antibodies, IgG and IgM) were measured by ELISA (Aesculisa, Aesku Diagnostics, Wendelsheim, Germany) with a cutoff of 15 GPL/MPL for ACA and 15 U/mL for b2GPI. Serum Neutrophil gelatinase-associated lipocalin (sNGAL) was measured by ELISA kits (BioVendor, Brno, Czech Republic). Biochemical analysis such as serum creatinine (Cr), were measured by automated analyzer and finally estimated glomerular filtration rate (e-GFR) was calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI). Fifteen patients were positive for ACA IgG (31.9%), two for anti-b2GPI IgM (4.2%), and three for anti-b2GPI IgG (6.3%). Furthermore, three persons from control group were positive in anti-b2GPI IgG (14.27%). The serum level of anti-b2GPI IgG was significantly higher in patients compared to healthy controls (p = 0.013). The level of sNGAL (59.63 ± 41.5 ng/mL vs. 45.5 ± 21.5 ng/mL, p = 0.14) was not higher in hypertensive patients than in the age-sex-matched control group. Additionally, the sNGAL level was found to be directly and positively correlated in patients with positive ACA IgG (r2 = 0,945, p < 0.0001). These results demonstrate that autoimmunity may be one of the pathogenetic factors of hypertension and aPL antibodies might be a potential marker of renal involvement.

show abstract

Section: Discussionsupporting

confidence: 86%

“…Moreover, we excluded patients with thrombotic events, which may be a clinical manifestation of APS. Moreover, in this study we do not measure other autoantibodies such as anti-Angiotensin II, anti-atrial natriuretic peptide or gene polymorphisms which may play role in the pathogenesis of hypertension [25,26].…”

Section: Discussionmentioning

confidence: 99%

Study of Antiphospholipid Antibodies in Patients with Arterial Hypertension

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Apart from the use of S100B protein as a TBI trauma biomarker, recent studies also indicate other possible applications. This protein can also be used as a predictor of hypertension 18 ; however, in our cohort, no correlation between S100B protein and hypertension was proven. Current knowledge of the S100B protein and its uses is beyond the scope of this communication.…”

Section: Discussioncontrasting

confidence: 70%

S100B protein as a biomarker and predictor in traumatic brain injury

Trnka¹,

Stejskal²,

Jablonský³

et al. 2024

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Objectives. To determine the prognostic potential of S100B protein in patients with craniocerebral injury, correlation between S100B protein and time, selected internal diseases, body habitus, polytrauma, and season. Methods. We examined the levels of S100B protein in 124 patients with traumatic brain injury (TBI). Results. The S100B protein level 72 h after injury and changes over 72 h afterwards are statistically significant for prediction of a good clinical condition 1 month after injury. The highest sensitivity (81.4%) and specificity (83.3%) for the S100B protein value after 72 h was obtained for a cut-off value of 0.114. For the change after 72 h, that is a decrease in S100B value, the optimal cut-off is 0.730, where the sum of specificity (76.3%) and sensitivity (54.2%) is the highest, or a decrease by 0.526 at the cut-off value, where sensitivity (62.5%) and specificity (62.9%) are more balanced. The S100B values were the highest at baseline; S100B value taken 72 h after trauma negatively correlated with GCS upon discharge or transfer (r=-0.517, P<0.0001). We found no relationship between S100B protein and hypertension, diabetes mellitus, BMI, or season when the trauma occurred. Changes in values and a higher level of S100B protein were demonstrated in polytraumas with a median of 1.070 (0.042; 8.780) μg/L compared to isolated TBI with a median of 0.421 (0.042; 11.230) μg/L. Conclusion. S100B protein level with specimen collection 72 h after trauma can be used as a complementary marker of patient prognosis.

show abstract

“…9 Further, Sherstnev et al have indicated that serum levels of S100B can be used as possible predictors of arterial hypertension. 32 Possibly, increased S100B level in hypertensive patients is an adaptive response to catecholamines enhancement in these subjects. 33,34 It has been reported that catecholamine injection induces S100B mRNA and protein in myocardial tissue, ventricular myocytes and increased S100B in arterial tissues.…”

Section: Discussionmentioning

confidence: 99%